SBIR Phase I: Endogenously secreted bispecific natural killer cell engagers (BIKEs) for th — NSF Award to WALIA, RAMPYARI (CA, $27
This Small Business Innovation Research (SBIR) Phase I project provides a novel, intramuscular gene delivery platform that supports sustained expression of any therapeutic protein, a capability yet to be commercially realized. The ability to provide sustained expression and endogenous secretion of bispecific natural ki
| Award title | SBIR Phase I: Endogenously secreted bispecific natural killer cell engagers (BIKEs) for th |
|---|---|
| Award ID | 2322959 |
| Awardee | WALIA, RAMPYARI |
| City | EL CAJON |
| State | CA |
| Amount obligated | $275,000 |
| Principal investigator | Rampyari Walia |
| Program | SBIR Phase I |
| Start date | 01/15/2024 |
| Abstract | This Small Business Innovation Research (SBIR) Phase I project provides a novel, intramuscular gene delivery platform that supports sustained expression of any therapeutic protein, a capability yet to be commercially realized. The ability to provide sustained expression and endogenous secretion of bispecific natural killer cell engager (BiKE) therapeutics is expected to be paradigm shifting by providing a solution that bypasses current immunotherapy treatments for solid tumors. This approach, wh |
| Source | NSF Awards |
$799/mo
Try NSFGrants →